Al peptide [13] but is not recapitulated by a muscle-specific transgene encoding

Al peptide [13] but is not recapitulated by a muscle-specific transgene encoding IGF-1 lacking an E-peptide moiety, which produces no local effects but instead significantly increases serum IGF-1 levels [14]. The dramatic phenotypes resulting from supplemental tissue-specific IGF-1Ea transgene expression in other tissues such as heart [15] and skin [16], with no increase in circulating IGF-1 levels, suggests a role for E-peptides in local IGF-1 action and retention of IGF-1 in the tissue of synthesis. To directly test this hypothesis, we analyzed transgenic mice expressing each of the four major IGF-1 prepropeptides under the control of a muscle-specific regulatory element and assessed the presence of transgene products in circulation. We investigated the relative retention of various IGF-1 moieties on decellularized tissue preparations. Here we show that both IGF-1Ea and IGF-1Eb propeptides bind extracellular matrix with significantly higher affinity than does mature IGF-1. E-peptide-mediated ECM binding is independent of the mature IGF-1 sequence, since theyE-Peptides Control Bioavailability of IGF-Figure 1. Structure of the rodent IGF-1 gene. Exons 1 and 2 are transcribed from different promoters. Differential splicing gives rise to two different signal peptides (SP1 and SP2), which include a common C-terminal sequence encoded by Exon 3. Exon 3 also encodes the N-terminal part of the mature IGF-1 B chain. Exon 4 encodes the remaining mature IGF-1 protein (B,C,A and D chains), and also encodes the common N-terminal sequence of the E-peptides. Differential splicing excluding Exon 5 gives rise to the IGF-1Ea propeptide, or a longer IGF-1Eb propeptide when Exon 5 18297096 is included. Protease cleavage (arrowheads) removes the E peptides to produce the mature IGF-1 protein. doi:10.1371/journal.pone.0051152.galso facilitate ECM binding when fused to relaxin, another insulinrelated factor. These results suggest a novel role for E-peptides in controlling bioavailability of IGF-1, by tethering the protein to the site of synthesis through enhanced affinity for the extracellular matrix.transgenic products are retained in the tissue of synthesis as propeptides. On the contrary, transgenic mice expressing mature IGF-1 (lacking E-peptide) driven by rat skeletal a-actin promoter showed increased levels of systemic IGF-1 [14,19], implicating the E peptide moiety in the retention of IGF-1 at the site of synthesis.Results Transgenic IGF-1 Propeptides are Retained in Skeletal MuscleTransgenic mice were generated with the four main IGF-1 splicing variants, combining the two signal peptides and two E peptides (Figure 1), controlled by the fast IIB muscle fiber-specific myosin light chain promoter (MLC1/3) and enhancer ([11], which drive expression exclusively in skeletal muscle (See Materials and Methods section). Western blot analysis of quadriceps muscles showed comparable IGF-1 protein levels in the four transgenic lines, which did not reflect variable transcript levels as revealed by Northern blot (Figure S1) suggesting that isoform concentration may be controlled post-transcriptionally. The majority of the transgenic protein was unprocessed or partially processed (Figure 2A). Additional bands likely reflect differential glycosylation states, since the rodent Ea-peptide contains two N-linked glycosylation sites that are absent in the order Emixustat (hydrochloride) Eb-peptide [17,18]. Total serum analysis revealed no increase in IGF-1 levels in mice carrying IGF-1Eb CI 1011 transgenes and only a s.Al peptide [13] but is not recapitulated by a muscle-specific transgene encoding IGF-1 lacking an E-peptide moiety, which produces no local effects but instead significantly increases serum IGF-1 levels [14]. The dramatic phenotypes resulting from supplemental tissue-specific IGF-1Ea transgene expression in other tissues such as heart [15] and skin [16], with no increase in circulating IGF-1 levels, suggests a role for E-peptides in local IGF-1 action and retention of IGF-1 in the tissue of synthesis. To directly test this hypothesis, we analyzed transgenic mice expressing each of the four major IGF-1 prepropeptides under the control of a muscle-specific regulatory element and assessed the presence of transgene products in circulation. We investigated the relative retention of various IGF-1 moieties on decellularized tissue preparations. Here we show that both IGF-1Ea and IGF-1Eb propeptides bind extracellular matrix with significantly higher affinity than does mature IGF-1. E-peptide-mediated ECM binding is independent of the mature IGF-1 sequence, since theyE-Peptides Control Bioavailability of IGF-Figure 1. Structure of the rodent IGF-1 gene. Exons 1 and 2 are transcribed from different promoters. Differential splicing gives rise to two different signal peptides (SP1 and SP2), which include a common C-terminal sequence encoded by Exon 3. Exon 3 also encodes the N-terminal part of the mature IGF-1 B chain. Exon 4 encodes the remaining mature IGF-1 protein (B,C,A and D chains), and also encodes the common N-terminal sequence of the E-peptides. Differential splicing excluding Exon 5 gives rise to the IGF-1Ea propeptide, or a longer IGF-1Eb propeptide when Exon 5 18297096 is included. Protease cleavage (arrowheads) removes the E peptides to produce the mature IGF-1 protein. doi:10.1371/journal.pone.0051152.galso facilitate ECM binding when fused to relaxin, another insulinrelated factor. These results suggest a novel role for E-peptides in controlling bioavailability of IGF-1, by tethering the protein to the site of synthesis through enhanced affinity for the extracellular matrix.transgenic products are retained in the tissue of synthesis as propeptides. On the contrary, transgenic mice expressing mature IGF-1 (lacking E-peptide) driven by rat skeletal a-actin promoter showed increased levels of systemic IGF-1 [14,19], implicating the E peptide moiety in the retention of IGF-1 at the site of synthesis.Results Transgenic IGF-1 Propeptides are Retained in Skeletal MuscleTransgenic mice were generated with the four main IGF-1 splicing variants, combining the two signal peptides and two E peptides (Figure 1), controlled by the fast IIB muscle fiber-specific myosin light chain promoter (MLC1/3) and enhancer ([11], which drive expression exclusively in skeletal muscle (See Materials and Methods section). Western blot analysis of quadriceps muscles showed comparable IGF-1 protein levels in the four transgenic lines, which did not reflect variable transcript levels as revealed by Northern blot (Figure S1) suggesting that isoform concentration may be controlled post-transcriptionally. The majority of the transgenic protein was unprocessed or partially processed (Figure 2A). Additional bands likely reflect differential glycosylation states, since the rodent Ea-peptide contains two N-linked glycosylation sites that are absent in the Eb-peptide [17,18]. Total serum analysis revealed no increase in IGF-1 levels in mice carrying IGF-1Eb transgenes and only a s.